Joseph S. Shan,Nikoletta L. Kallinteris,Min Tang,F. Andrew Dorr
申请号：
US15943304
公开号：
US20180289771A1
申请日:
2018.04.02
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Disclosed are surprising new methods and kits for treating patients, particularly cancer patients, using bavituximab in combination therapies with immuno-oncology (IO) agents such as checkpoint inhibitor antibodies. The methods and kits are based on the surprising finding that human patients treated with bavituximab and checkpoint inhibitor antibodies have a statistically significant prolonged survival in controlled studies.
